SCHEMBL1706430

SCHEMBL1706430

CC(=O)c1nc(Br)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17190682 0.85 GRM5 (0.46)
SCHEMBL168669 0.82
SCHEMBL1032888 0.80
SCHEMBL169576 0.80
SCHEMBL531468 0.80
SCHEMBL1476030 0.79 GRM5 (0.55)
SCHEMBL17716399 0.79 GRM5 (0.44)
SCHEMBL1682676 0.79 GRM5 (0.48)
SCHEMBL1669191 0.77 KDM1A (0.49)
SCHEMBL929092 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-12624010-B2 Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway AC IMMUNE SA (CH) 2026-05-12 US disclosed
EP-4168395-B1 DIHYDROOXAZOLE AND THIOUREA OR UREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY AC IMMUNE SA (CH) 2026-03-25 EP disclosed
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 US disclosed
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 WO disclosed
CN-114555570-B Oral complement factor D inhibitors 拜奥克里斯特制药公司 2024-09-13 CN disclosed
EP-2318006-A1 NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS N30 Pharmaceuticals, LLC (US) 2011-05-11 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed
WO-2010019903-A1 NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS N30 PHARMACEUTICALS, LLC (US) 2010-02-18 WO disclosed
WO-2010019903-A1 NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS N30 PHARMACEUTICALS, LLC (US) 2010-02-18 WO disclosed
EP-1232149-A2 FUNGICIDAL MELITHIAZOLE DERIVATIVES Gesellschaft für biotechnologische Forschung mbH (GBF) (DE) 2002-08-21 EP disclosed
WO-2001038317-A2 FUNGICIDAL MELITHIAZOLE DERIVATIVES GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) 2001-05-31 WO disclosed
CN-1012365-B 2- (N-substituted guanidino) -4-heteroaryl thiazole antiulcer agent and its preparation method PFIZER (US) 1991-04-17 CN disclosed
CN-85103265-A The method of preparation 2-(guanidine radicals that N-replaces)-4-heteroaryl thiazole anti ulcer agent 1986-12-10 CN disclosed